Navigation Links
Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
Date:6/5/2008

SOUTH SAN FRANCISCO, Calif., June 5 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that it has out-licensed all worldwide rights to its NF-kappa B Decoy (NF-kB Decoy) program, which includes the clinical drug candidate Avrina(TM), to Transcription Factor Therapeutics, Inc. (TFT). NF-kB Transcription Factor Decoy inhibits NF-kappa B, a protein implicated in the inflammatory cascade in diseases such as inflammatory bowel disease (IBD), eczema, rheumatoid arthritis, and asthma.

Under the terms of the agreement, Anesiva will receive an upfront license fee, with additional payments dependent on development and regulatory milestones potentially totaling up to $114 million if two products are commercialized. Anesiva would also be entitled to royalty payments upon successful commercialization of any drug candidate(s). Additional terms were not disclosed. TFT will be responsible for the future development of Avrina(TM), and intellectual property associated with the NF-kB Decoy program will be transferred to TFT.

"Anesiva considers TFT a capable development organization to move this program forward," said John P. McLaughlin, chief executive officer of Anesiva. "With a strong focus on anti-inflammatory transcription factor decoys, we believe that TFT is well positioned to advance the NF-kappa B program, which holds great potential to impact the treatment of inflammatory diseases."

TFT initially plans to take Avrina(TM), a highly potent and selective inhibitor of NF-kappa B, into clinical trials in IBD in 2009. Avrina has shown highly encouraging results in multiple preclinical models of both Crohn's Disease and ulcerative colitis, two forms of IBD. These results have been well received in international sc
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Anesiva Announces First Quarter 2008 Financial Results
2. Anesiva Announces First Quarter 2008 Financial Results Conference Call and Webcast
3. Anesiva Announces Expansion of Zingo Agreement in Europe
4. Anesiva Announces New Zingo Marketing and Distribution Agreement
5. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
6. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
7. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
8. Anesiva Appoints Daniel Janney to Board of Directors
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Announces Completion of Common Stock Offering
11. Anesiva Raises $45 Million in Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Array BioPharma Inc. (NASDAQ: ARRY ... agreement with Novartis Pharma AG to acquire worldwide rights ... 3 development.  This agreement is conditional on the closing of ... 22, 2014, which are expected to close in the ...
(Date:1/22/2015)... BOSTON , Jan. 22, 2015  Transwestern | RBJ today ... feet of office space for Shire a leading biopharmaceutical company, ... . Transwestern | RBJ,s Robert Richards , president, and ... the lease for the entire five-floor building at 95 Hayden ...
(Date:1/22/2015)... laboratory information management systems market is a rapidly growing ... due to factors such as rising pressure to comply ... and increasing government support for adoption of HCIT solutions ... the market focus on technological advancements to further the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 zFlo Motion ... pleased to announce an exciting product from a new partner. ... analysis solutions over the past 15 years, with offerings in ... recently, their 3D IMU system (inertial measurement unit), iSen, is ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 43D Motion Capture Just Got Easy 2
... for the First Three Months of 2008., COPENHAGEN, May ... three month period ended March 31, 2008.,During this period, Genmab ... million (approx. USD 36 million) for the,first quarter of 2008. ... 80 million (approx. USD 17 million)., An operating loss ...
... SoluLinK, Inc., a leader in,next-generation conjugation products ... of a new product, NanoLink(TM) Streptavidin Magnetic,Microspheres. ... of any commercially available polymer-encapsulated streptavidin,magnetic microsphere. ... throughput robotic applications where high biotin loads,must ...
... 28 The automation of,transaction-based processing is ... the United States. Foresight Corporation of Dublin, ... scale of installations of Transaction,Insight(R) - the ... Transaction automation techniques enable healthcare organizations to,cut ...
Cached Biology Technology:Genmab Announces 2008 First Quarter Results 2Genmab Announces 2008 First Quarter Results 3Genmab Announces 2008 First Quarter Results 4SoluLinK Introduces NanoLink(TM) Streptavidin Magnetic Microspheres 2New Trend Sweeping Nation's Health Plans: Transaction Automation 2
(Date:1/22/2015)... , January 22, 2015 , ... tenth year  The European Patent Office to present a ... Two British nominations to be featured: Christofer Toumazou and ... featuring former finalists and winners of the Award   ...
(Date:12/22/2014)... 2014  NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... the growing mobile commerce market, announces it has retained famous ... the 2015 International CES debut of the Wocket™ biometric smart ... at the NXT-ID booth January 6th and 7 th , ...
(Date:12/19/2014)... MOUNTAIN VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., ... a study that pinpoints fine-scale differences in genetic ancestry of ... Since immigrants first arrived more than four hundred ... served as a meeting place for peoples from different continents. ...
Breaking Biology News(10 mins):Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... mutations in BRCA1 and BRCA2 genes have a significantly higher ... risk have been seeking genetic testing and counseling based on ... sequencing is labor-intensive, costly, and it only targets a part ... Canadian scientists has developed a new sequencing approach to provide ...
... emerged centuries ago in Europe has now been ... industrialization. Unlike other diarrheal diseases, this one is ... clean water. As developing countries become more industrialized ... flexneri are known to decline, associated with ...
... (DOE) announced Aug. 2 that a team of engineers ... million to design a battery management system for lithium-ion ... This is a particularly challenging project because the electrochemical ... mathematical form. The project is one of 12 ...
Cached Biology News:New method provides fast, accurate, low cost analysis of BRCA gene mutations in breast cancer 2Out of Europe 2Out of Europe 3$3.2 million to develop battery management system for electric-car batteries 2$3.2 million to develop battery management system for electric-car batteries 3$3.2 million to develop battery management system for electric-car batteries 4
Human sIL-2R/CD25 ELI-PAIR Kit...
Request Info...
ANTI-HUMAN CYTOKINES, GROWTH FACTORS (polyclonal rabbit (or goat) antibodies) Human TARC - Biotin...
Anti-Bcl-G (CT) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
Biology Products: